EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- ATH434 protects brain cells and improves motor function
- Alterity to present at Global Life Science Conference
- Michael J Fox grant for Parkinsons research on ATH434
- Alterity participates in JP Morgan healthcare conference
- Dr David Stamler Appointed CEO
Later from Alterity Therapeutics
- New US patent targeting major neurodegenerative diseases
- New Publication Demonstrates ATH434 is Neuroprotective
- New US Patent Expands Neurodegeneration Treatment Portfolio
- Appendix 4E & Annual Report 2021
- Form 20-F
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics